On May 23, 2024, Radar Therapeutics Inc closed the transaction. The company received $13,400,000 in a round of funding led by a new investor, NFX Capital Management, LLC. The transaction included participation from new investors, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors.